Amedco - Quiz

2019 MOC Postgraduate

 
 

A   - Aortic arch
B   - Upper esophageal sphincter
C   - Gastroesophageal junction
D   - Transition of skeletal muscle to smooth muscle

A   - Orange juice
B   - Sucralfate
C   - Aluminum hydroxide
D   - Honey

A   - Injection therapy alone
B   - Thermal therapy alone
C   - Injection therapy in combination with another method
D   - Hemopowder therapy

A   - Resolution of symptoms and normalization of the tTG antibodies correlate with gut mucosal outcome and adherence to the gluten free diet.
B   - Approximately 4-19% of children with celiac disease show persistent enteropathy even if they adhere to a gluten free diet.
C   - There are currently approved therapies alternative/complementary to the gluten free diet on the market for the management of celiac disease.

A   - Hypersplenism (thrombocytopenia)
B   - Variceal bleeding
C   - Worsening fat-soluble vitamin deficiency
D   - All of the above

A   - True
B   - False

A   - There are no FDA approved uses for cannabis products.
B   - There is more data on the benefit of CBD than for THC.
C   - There is very limited data on the potential benefits for IBD.
D   - For IBD, edible cannabis is more effective than smoked cannabis.

A   - Stool calprotectin
B   - Erythrocyte sedimentation rate
C   - Abdominal ultrasound
D   - Upper GI endoscopy

A   - Results of diagnostic laboratory tests
B   - Thorough history
C   - Results of imaging studies
D   - Evaluation of effectiveness of medical therapy

A   - Integrated relaxation pressure (IRP)
B   - Distal contractile integral (DL)
C   - Distal latency (DL)
D   - Esophagogastric junction contractile integral (EGJ-CI)

A   - Stop PPI and start Carafate
B   - Stop PPI and proceed with impedance-ph monitoring
C   - Continue PPI and proceed with esophageal manometry
D   - Refer to surgeon for an antireflux surgery

A   - Gas production
B   - Inflammation
C   - Visceral hypersensitivity
D   - Allergy
E   - Fermentation

A   - Inflammation, hepatocyte ballooning, steatosis and fibrosis
B   - Inflammation and hepatocyte ballooning
C   - Inflammation, hepatocyte ballooning and steatosis
D   - Inflammation, microvesicular fat and macrovesicular fat

A   - Increased bile acid conjugation
B   - Reduced hepatic bile acids
C   - Reduced colonic bile acids
D   - Activation of FXR

A   - 2%
B   - 8%
C   - 10%
D   - 20%

A   - Ductal adenocarcinoma
B   - Acinar carcinoma
C   - Pancreatoblastoma
D   - Solid pseudopapillary tumor

A   - Male sex
B   - Prior surgery
C   - Shorter duration of disease
D   - Failure of prior biological therapy

A   - Stopping immunomodulator after 6 months of combination therapy has no effect on infliximab trough levels.
B   - In the SONIC study, infliximab trough levels were higher in patients receiving combination (versus mono-) therapy.
C   - In the SONIC study, likelihood of corticosteroid free remission was greater with combination therapy regardless of trough level quartile.
D   - Emerging data suggest that induction with optimized infliximab monotherapy guided by early TDM avoids anti-drug antibody development as effectively as combination therapy.

A   - Proton pump inhibitors
B   - Antibiotics
C   - H2 blockers
D   - NSAIDs

A   - Mucosa
B   - Muscularis
C   - Serosa